Tau silencing by siRNA in the P301S mouse model of tauopathy.

Suppression of tau protein expression has been shown to improve behavioral deficits in mouse models of tauopathies, offering an attractive therapeutic approach. Experimentally this had been achieved by switching off the promoters controlling the transgenic human tau gene (MAPT), which is not possible in human patients. The aim of the present study was therefore to evaluate the effectiveness of small interfering RNAs (siRNAs) and their cerebral delivery to suppress human tau expression in vivo, which might be a therapeutic option for human tauopathies. We used primary cortical neurons of transgenic mice expressing P301S-mutated human tau and Lund human mesencephalic (LUHMES) cells to validate the suppressive effect of siRNA in vitro. For measuring the effect in vivo, we stereotactically injected siRNA into the brains of P301S mice to reveal the suppression of tau by immunochemistry (AT180, MC1, and CP13 antibodies). We found that the Accell™ SMART pool siRNA against MAPT can effectively suppress tau expression in vitro and in vivo without a specific delivery agent. The siRNA showed a moderate distribution in the hippocampus of mice after single injection. NeuN, GFAP, Iba-1, MHC II immunoreactivities and the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay showed neither signs of neurotoxicity or neuroinflammation nor apoptosis when MAPT siRNA is present in the hippocampus. Our data suggest that siRNA against MAPT can serve as a potential tool for gene therapy in tauopathies.

[1]  C. Culmsee,et al.  Trifluoperazine rescues human dopaminergic cells from wild-type α-synuclein-induced toxicity , 2014, Neurobiology of Aging.

[2]  Kwong Wai Choy,et al.  Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. , 2014, Gene.

[3]  J. Michel,et al.  Modifications of Chromatin Dynamics Control Smad2 Pathway Activation in Aneurysmal Smooth Muscle Cells , 2013, Circulation research.

[4]  E. Mandelkow,et al.  Regulatable transgenic mouse models of Alzheimer disease: onset, reversibility and spreading of Tau pathology , 2013, The FEBS journal.

[5]  D. Holtzman,et al.  Antisense Reduction of Tau in Adult Mice Protects against Seizures , 2013, The Journal of Neuroscience.

[6]  S. Ravi,et al.  Mitochondria and AMP-activated Protein Kinase-dependent Mechanism of Efferocytosis* , 2013, The Journal of Biological Chemistry.

[7]  Michel Goedert,et al.  Tau pathology and neurodegeneration , 2013, The Lancet Neurology.

[8]  Meaghan Morris,et al.  Age-appropriate cognition and subtle dopamine-independent motor deficits in aged Tau knockout mice , 2013, Neurobiology of Aging.

[9]  Markus Tolnay,et al.  “Prion‐Like” Templated Misfolding in Tauopathies , 2013, Brain pathology.

[10]  B. Davidson,et al.  Recent Advances in RNA Interference Therapeutics for CNS Diseases , 2013, Neurotherapeutics.

[11]  J. Trojanowski,et al.  Synthetic Tau Fibrils Mediate Transmission of Neurofibrillary Tangles in a Transgenic Mouse Model of Alzheimer's-Like Tauopathy , 2013, The Journal of Neuroscience.

[12]  Jongdoo Lim,et al.  Triazine dendrimers as drug delivery systems: from synthesis to therapy. , 2012, Advanced drug delivery reviews.

[13]  H. Nakajima,et al.  A rapid, targeted, neuron-selective, in vivo knockdown following a single intracerebroventricular injection of a novel chemically modified siRNA in the adult rat brain. , 2012, Journal of biotechnology.

[14]  Ryan M Spengler,et al.  Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  Vineet Kumar,et al.  Nanocarriers: a tool to overcome biological barriers in siRNA delivery , 2011, Expert opinion on biological therapy.

[16]  B. S. Manjunath,et al.  Silencing of CDK5 Reduces Neurofibrillary Tangles in Transgenic Alzheimer's Mice , 2010, The Journal of Neuroscience.

[17]  M. Lock,et al.  Efficient serotype-dependent release of functional vector into the culture medium during adeno-associated virus manufacturing. , 2010, Human gene therapy.

[18]  W. Filipowicz,et al.  The widespread regulation of microRNA biogenesis, function and decay , 2010, Nature Reviews Genetics.

[19]  J. Henderson,et al.  α-Synuclein Suppression by Targeted Small Interfering RNA in the Primate Substantia Nigra , 2010, PloS one.

[20]  E. Alleva,et al.  Early behavioural markers of disease in P301S tau transgenic mice , 2010, Behavioural Brain Research.

[21]  S. Snyder,et al.  GOSPEL: A Neuroprotective Protein that Binds to GAPDH upon S-Nitrosylation , 2009, Neuron.

[22]  M. Zern,et al.  Short hairpin RNA causes the methylation of transforming growth factor-beta receptor II promoter and silencing of the target gene in rat hepatic stellate cells. , 2007, Biochemical and Biophysical Research Communications - BBRC.

[23]  A. Aigner,et al.  RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. , 2006, Human gene therapy.

[24]  A. Aigner.  Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs. , 2006, Journal of biotechnology.

[25]  J. Lucas,et al.  Full Reversal of Alzheimer's Disease-Like Phenotype in a Mouse Model with Conditional Overexpression of Glycogen Synthase Kinase-3 , 2006, The Journal of Neuroscience.

[26]  B. Hyman,et al.  Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function , 2005, Science.

[27]  C. Henderson,et al.  Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS , 2005, Nature Medicine.

[28]  F. Natt,et al.  Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[29]  F. Natt,et al.  siRNA relieves chronic neuropathic pain. , 2004, Nucleic acids research.

[30]  H. Paulson,et al.  Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles. , 2004, Nucleic acids research.

[31]  V. Ambros,et al.  Role of MicroRNAs in Plant and Animal Development , 2003, Science.

[32]  C. Culmsee,et al.  Nerve growth factor survival signaling in cultured hippocampal neurons is mediated through TrkA and requires the common neurotrophin receptor P75 , 2002, Neuroscience.

[33]  Hirotaka Yoshida,et al.  Abundant Tau Filaments and Nonapoptotic Neurodegeneration in Transgenic Mice Expressing Human P301S Tau Protein , 2002, The Journal of Neuroscience.

[34]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[35]  Haibin Xia,et al.  A simple method for the rapid generation of recombinant adenovirus vectors , 2000, Gene Therapy.

[36]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[37]  V. Torchilin,et al.  siRNA delivery: from basics to therapeutic applications. , 2013, Frontiers in bioscience.

[38]  M. Goedert,et al.  Molecular Pathogenesis of Genetic and Inherited Diseases Induction of Inflammatory Mediators and Microglial Activation in Mice Transgenic for Mutant Human P301S Tau Protein , 2004 .